一种用于新型放射性核素定量临床影像试验的PET和SPECT设备验证方法
本文报告了一套用于校准和验证PET与SPECT定量图像准确性和质量保证的方法,适用于半衰期较长的非标准放射性核素(如124I PET和131I SPECT)的临床影像试验。该方法采用三步法,使用NEMA NU-2 IEC图像质量体模,在澳大利亚7个中心的10台PET/CT和8台SPECT/CT系统上实施;1台PET/CT系统的SUVavg结果超出1.0±0.05的规格,所有SPECT/CT系统的SUVavg准确度在真值±10%以内(SUVmean 1.0±0.1)。
要点
- 三步法:先用已校准核素在简单几何中检查定量准确性,再用试验用新型核素在相同几何中检查,最后在NEMA NU-2 IEC图像质量体模中检查。
- PET准确性基于将剂量校准器校准至可对18F以外核素产生定量图像,所有图像在各中心PET系统上重建;SPECT则独立测量灵敏度后用于校准核心实验室重建的SPECT图像。
- 澳大利亚7个中心的10台PET/CT(124I)和8台SPECT/CT(131I)通过验证;1台PET/CT的SUVavg超出1.0±0.05规格,所有SPECT/CT的SUVavg在真值±10%以内(SUVmean 1.0±0.1)。
核心结论
- 已开发出一套通用方法,用于在临床试验中校准和验证PET与SPECT系统的定量成像。
- 测试体模和操作流程相对简单,通常可由影像中心现场工作人员使用临床试验机构提供的设备实施。
研究设计与样本
- 方法学报告:开发并实施用于非标准放射性核素(示例为124I PET和131I SPECT)定量PET和SPECT图像校准的三步法流程。
- 在澳大利亚7个中心对10台PET/CT扫描仪(124I成像)和8台SPECT/CT系统(131I)进行资格验证。
主要发现
- 1台PET/CT系统的结果超出SUVavg 1.0±0.05的规格。
- 所有SPECT/CT系统的SUVavg准确度在重建放射性浓度真值(Bq/cm3)的±10%以内(SUVmean 1.0±0.1)。
关键数值与推荐
- PET定量准确性基于将剂量校准器校准至可对18F以外核素产生定量图像,所有图像在各中心PET系统上重建。
- SPECT先独立测量灵敏度,再用于校准核心实验室重建的SPECT图像。
- 最终测试使用NEMA NU-2 IEC图像质量体模,导出包括基于SUVavg的定量准确性在内的多项指标。
- PET/CT的SUVavg规格为1.0±0.05;SPECT/CT的SUVavg准确度需在真值±10%以内(SUVmean 1.0±0.1)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Our aim is to report methodology that has been developed to calibrate and verify PET and SPECT quantitative image accuracy and quality assurance for use with nonstandard radionuclides, especially with longer half-lives, in clinical imaging trials. Methods: Procedures have been developed for quantitative PET and SPECT image calibration for use in clinical trials. The protocol uses a 3-step approach: check quantitative accuracy with a previously calibrated radionuclide in a simple geometry, check the novel trial radionuclide in the same geometry, and check the novel radionuclide in a more challenging, complex geometry (the National Electrical Manufacturers Association [NEMA] NU-2 International Electrotechnical Commission [IEC] image-quality phantom). The radionuclides used in the trial as an example are 124I (PET) and 131I (SPECT). In both cases, whole-body tomographic SPECT and PET imaging with accompanying low-dose CT are required. PET accuracy is based on calibrating the dose calibrator to produce quantitative images for radionuclides other than 18F, with all images reconstructed on each individual site's PET systems. For SPECT, an independent sensitivity measurement is made and then used to calibrate the SPECT images reconstructed at the core laboratory. After calibration, the final testing for both PET and SPECT uses the NEMA NU-2 IEC image-quality phantom to derive several metrics including quantitative accuracy based on an average SUV (SUVavg). Results: Using the method described, 7 sites in Australia have been qualified for 10 PET/CT scanners using 124I imaging and 8 SPECT/CT systems for 131I. One PET/CT system was found to give a result outside the specification of an SUVavg of 1.0 ± 0.05. All SPECT/CT systems gave an SUVavg accurate to within ±10% (SUVmean, 1.0 ± 0.1) of the true value for reconstructed radioactivity concentration in Bq/cm3 Conclusion: A general methodology has been developed to calibrate and validate PET and SPECT systems for quantitative imaging in clinical trials. The preparation of the test objects and the procedures is relatively simple and can generally be implemented by the staff at the site of the imaging center with the equipment supplied by the clinical trials organization.
引用
- Bailey DL, Willowson KP, O'Keefe G, et al. A Method for Validating PET and SPECT Cameras for Quantitative Clinical Imaging Trials Using Novel Radionuclides. J Nucl Med. 2025. PMID: 39819695. doi:10.2967/jnumed.124.268578
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。